Jazz Pharmaceuticals plc – Ordinary Shares (JAZZ) was Reiterated by UBS to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 168 from a previous price target of $162 . UBS advised their investors in a research report released on May 11, 2016.
Many Wall Street Analysts have commented on Jazz Pharmaceuticals plc – Ordinary Shares. Company shares were Upgraded by Mizuho on May 11, 2016 to ” Buy”, Firm has raised the Price Target to $ 193 from a previous price target of $137 .Jazz Pharmaceuticals plc – Ordinary Shares was Upgraded by Sun Trust Rbsn Humphrey to ” Buy” on Apr 25, 2016. Shares were Reiterated by Mizuho on Feb 24, 2016 to “Neutral” and Lowered the Price Target to $ 124 from a previous price target of $140 .
On the company’s financial health, Jazz Pharmaceuticals plc – Ordinary Shares reported $2.26 EPS for the quarter, missing the analyst consensus estimate by $ -0.06 based on the information available during the earnings call on May 10, 2016. Analyst had a consensus of $2.32. The company had revenue of $336.01 million for the quarter, compared to analysts expectations of $340.17 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.99 EPS.
Jazz Pharmaceuticals plc – Ordinary Shares opened for trading at $148.78 and hit $148.99 on the upside on Tuesday, eventually ending the session at $147.82, with a gain of 0.09% or 0.13 points. The heightened volatility saw the trading volume jump to 9,60,396 shares. Company has a market cap of $8,935 M.
In a different news, on Apr 27, 2016, Karen J Wilson (SVP, Finance & PAO) sold 604 shares at $160.00 per share price. According to the SEC, on Apr 18, 2016, Michael Patrick Miller (SVP, US Commercial) sold 100 shares at $145.79 per share price. On Apr 13, 2016, Russell J. Cox (EVP & COO) sold 4,000 shares at $136.98 per share price, according to the Form-4 filing with the securities and exchange commission.